Why is Ocugen (OCGN) stock soaring? Here's what you must know

February 23, 2022 03:21 AM EST | By Raza Naqvi
Follow us on Google News:
Highlights:
  • On February 22, Ocugen announced the pricing of its underwritten public offering.
  • Dr Shankar Musunuri, chief executive officer and co-founder of Ocugen said that the company can now move COVAXIN™'s clinical program forward.
  • Ocugen is expected to continue the phase 3 study for securing Emergency Use Authorization (EUA) of the vaccine in the United States.

Stocks of Ocugen, Inc. (NASDAQ:OCGN) surged 22.3 per cent on Tuesday, February 22, as investors responded positively to a significant development announced by the company on Friday, February 18.

As markets remained closed on Monday due to President's Day celebrations, the surge in the share prices came at the start of the trading session.

On Friday, the Food and Drug Administration (FDA) lifted the clinical hold on Ocugen's Investigational New Drug (IND) application.

Also Read: What is PayMongo and why is it grabbing attention?

The application was filed to evaluate the COVID-19 vaccine candidate called BBV152. Notably, the BBV152 vaccine is called COVAXIN™ outside of the United States.

In November last year, the FDA had placed a clinical hold on the IND application, which restricted Ocugen from starting its planned phase 3 study of the vaccine candidate.

What's next for Ocugen (NASDAQ:OCGN)

Dr Shankar Musunuri, chief executive officer and co-founder of Ocugen, said that the company can now move COVAXIN™'s clinical program forward.

Bharat Biotech developed COVAXIN™ through collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).

Ocugen (OCGN) stock                                                                                                   ©2022 Kalkine Media® 

Outside of the United States, more than 200 million doses of COVAXIN™ have been administered and 20 countries have authorized the vaccine for emergency use.

Ocugen is expected to continue the phase 3 study for securing Emergency Use Authorization (EUA) of the vaccine in the United States. Notably, the World Health Organization (WHO) also added COVAXIN™ in the list of vaccines for emergency use.

Bottom line

On February 22, Ocugen announced the pricing of a public offering. The company is set to offer 15,973,420 million shares of common stock for around US$ 53.5 million.

The underwritten public offering is expected to close on February 25, and the underwriter would have an option of purchasing 2.4 million additional shares within 30 days.

As per the company statement, Cantor Fitzgerald & Co. was given the underwriting responsibility for the proposed offering.

Also Read: Can you buy TRUTH Social stock?

Ocugen is offering the common stock pursuant to a registration statement filed the Securities and Exchange Commission. The company had previously filed Form S-3ASR on March 22 last year.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.



Top TSX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK